Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$118.51 +1.2%	$106.36	$75.56 ▼ $139.13	$5.91B	0.51	611,443 shs	727,981 shs
JANX Janux Therapeutics	$24.30 +1.3%	$24.51	$21.97 ▼ $71.71	$1.46B	2.86	923,446 shs	703,678 shs
NUVL Nuvalent	$76.08 +3.3%	$78.55	$55.53 ▼ $113.51	$5.49B	1.3	509,960 shs	407,091 shs
RNA Avidity Biosciences	$46.35 +3.8%	$35.63	$21.51 ▼ $56.00	$5.96B	0.95	3.90 million shs	1.89 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.17%	+8.52%	+11.42%	+12.79%	+34.81%
JANX Janux Therapeutics	+1.25%	-3.23%	-8.16%	-3.65%	-45.88%
NUVL Nuvalent	+3.30%	+0.05%	-5.47%	+3.52%	-7.96%
RNA Avidity Biosciences	+3.78%	-0.26%	+36.65%	+51.57%	+2.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.7994 of 5 stars	4.5	1.0	4.5	3.6	4.2	0.6
JANX Janux Therapeutics	2.0629 of 5 stars	3.5	3.0	0.0	1.2	1.7	0.0
NUVL Nuvalent	3.4012 of 5 stars	4.5	1.0	0.0	3.3	3.3	0.0
RNA Avidity Biosciences	3.1767 of 5 stars	4.5	2.0	0.0	3.9	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.07	Buy	$178.00	50.20% Upside
JANX Janux Therapeutics	3.08	Buy	$86.90	257.61% Upside
NUVL Nuvalent	3.08	Buy	$118.91	56.29% Upside
RNA Avidity Biosciences	3.06	Buy	$67.00	44.55% Upside

Current Analyst Ratings Breakdown

Latest JANX, RNA, NUVL, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	NUVL Nuvalent	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$112.00
8/18/2025	JANX Janux Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
8/8/2025	RNA Avidity Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$70.00 ➝ $75.00
8/8/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$59.00 ➝ $62.00
8/8/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
8/5/2025	AXSM Axsome Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$173.00 ➝ $176.00
8/5/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$184.00 ➝ $189.00
8/4/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$150.00
7/21/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
7/11/2025	RNA Avidity Biosciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	15.33	N/A	N/A	$1.46 per share	81.17
JANX Janux Therapeutics	$10.59M	137.88	N/A	N/A	$16.48 per share	1.47
NUVL Nuvalent	N/A	N/A	N/A	N/A	$13.03 per share	N/A
RNA Avidity Biosciences	$10.90M	547.06	N/A	N/A	$9.27 per share	5.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.07	N/A	42.02	N/A	-49.88%	-283.22%	-33.06%	11/11/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.80	N/A	N/A	N/A	N/A	-11.48%	-11.01%	11/5/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	11/11/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.56	N/A	N/A	N/A	-4,247.77%	-33.45%	-30.22%	11/6/2025 (Estimated)

Latest JANX, RNA, NUVL, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	JANX Janux Therapeutics	-$0.48	-$0.55	-$0.07	-$0.55	$0.30 million	N/A
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.00	-$0.92	+$0.08	-$0.97	$140.02 million	$150.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.66	1.57	1.51
JANX Janux Therapeutics	N/A	47.03	47.03
NUVL Nuvalent	N/A	13.57	13.57
RNA Avidity Biosciences	N/A	9.26	9.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
JANX Janux Therapeutics	75.39%
NUVL Nuvalent	97.26%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
JANX Janux Therapeutics	8.10%
NUVL Nuvalent	10.20%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.90 million	38.77 million	Optionable
JANX Janux Therapeutics	30	60.09 million	55.23 million	Optionable
NUVL Nuvalent	40	72.11 million	64.75 million	Optionable
RNA Avidity Biosciences	190	128.65 million	123.73 million	Optionable

JANX, RNA, NUVL, and AXSM Headlines

Recent News About These Companies

Avidity Biosciences (NASDAQ:RNA) Insider Sells $102,451.20 in Stock

August 23 at 9:18 AM | insidertrades.com

Candriam S.C.A. Increases Stock Position in Avidity Biosciences, Inc. $RNA

August 23 at 7:07 AM | marketbeat.com

Wellington Management Group LLP Has $285.89 Million Stock Holdings in Avidity Biosciences, Inc. $RNA

August 22 at 5:05 AM | marketbeat.com

Aberdeen Group plc Increases Holdings in Avidity Biosciences, Inc. $RNA

August 22 at 4:18 AM | marketbeat.com

Avidity Biosciences, Inc. $RNA Shares Sold by Swiss National Bank

August 22 at 3:29 AM | marketbeat.com

Avidity Biosciences Sees Unusually High Options Volume (NASDAQ:RNA)

August 21 at 7:12 PM | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Down 4.2% on Insider Selling

August 20 at 3:46 PM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $67.00 Consensus PT from Analysts

August 20 at 3:01 AM | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Stock Price Down 4.2% on Insider Selling

August 20 at 2:35 AM | americanbankingnews.com

Avidity Biosciences, Inc. $RNA Holdings Cut by Vanguard Group Inc.

August 19, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Citigroup Inc.

August 18, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by Deutsche Bank AG

August 18, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $465,600.00 in Stock

August 17, 2025 | marketbeat.com

Teresa Mccarthy Sells 10,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

August 16, 2025 | insidertrades.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Buy" by Analysts

August 16, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Down on Insider Selling

August 12, 2025 | marketbeat.com

What is Leerink Partnrs' Estimate for RNA FY2027 Earnings?

August 12, 2025 | marketbeat.com

Mackenzie Financial Corp Invests $213,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)

August 11, 2025 | marketbeat.com

Troy Edward Wilson Sells 65,554 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

August 10, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Steven George Hughes Sells 81,434 Shares

August 10, 2025 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells $5,119,150.00 in Stock

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

JANX, RNA, NUVL, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$118.51 +1.37 (+1.17%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$118.47 -0.04 (-0.03%)

As of 08/22/2025 07:55 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Janux Therapeutics NASDAQ:JANX

$24.30 +0.30 (+1.25%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$24.12 -0.18 (-0.72%)

As of 08/22/2025 05:25 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Nuvalent NASDAQ:NUVL

$76.08 +2.43 (+3.30%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$76.08 0.00 (0.00%)

As of 08/22/2025 05:25 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Avidity Biosciences NASDAQ:RNA

$46.35 +1.69 (+3.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$46.45 +0.10 (+0.22%)

As of 08/22/2025 07:52 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time